Trial reportAntimicrobial agents and chemotherapy2000
Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.
Trial report in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.Pulmonary pharmacology & therapeutics · 2022Review
- Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
- Emerging trends in inhaled drug delivery.Advanced drug delivery reviews · 2020Review
- Clinical pharmacokinetics of inhaled antimicrobials.Clinical pharmacokinetics · 2015Review
- Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.Advanced drug delivery reviews · 2015Review
- Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.Influenza and other respiratory viruses · 2013Review
- Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.Journal of virology · 2012Article
- Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.Emerging infectious diseases · 2012Article
- Article
- Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.PloS one · 2012Article
- Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.Antimicrobial agents and chemotherapy · 2011Article
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.Antimicrobial agents and chemotherapy · 2010Article
- CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.Antimicrobial agents and chemotherapy · 2009Article
- In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.Antimicrobial agents and chemotherapy · 2009Article
- Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.PLoS pathogens · 2008Article
- Treatment of respiratory virus infections.Antiviral research · 2006Review
- Avian influenza virus infections in humans.Chest · 2006Review
- Zanamivir: from drug design to the clinic.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2001Review
- Antiviral agents against respiratory viruses.Clinical microbiology newsletter · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.